Pepcid AC Gelcaps OTC Labeling Exemptions Sought By J&J/Merck
This article was originally published in The Tan Sheet
Executive Summary
J&J/Merck is requesting several exemptions from provisions of the OTC labeling final rule for sample pouches of the firm's Pepcid AC Gelcaps.
You may also be interested in...
Pepcid AC Gelcaps Sample Pouch Deferral Granted Without "Drug Facts" Title
J&J/Merck's request for a nine-month deferral from complying with the OTC labeling format for sample pouches of the company's H2 antagonist Pepcid AC Gelcaps has been granted.
Pepcid AC Gelcaps Nine-Month Deferral Sought By J&J/Merck
J&J/Merck has changed course in its efforts to obtain relief from provisions of the OTC labeling final rule for sample pouches of the firm's Pepcid AC Gelcaps.
Novartis Approvals Dominate Rx-To-OTC Switches In 1999
Novartis Consumer Health cornered the Rx-to-OTC switch landscape in 1999, receiving approval for and bringing to market former Rx drugs Lamisil AT and Habitrol.